Lovastatin Tablet
Product Images NDC 68788-7056

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 68788-7056). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg 100ct

Lovastatin Tablets USP 10 mg oral tablet label from Preferred Pharmaceuticals Inc. The label states the generic name Lovastatin, the strength of 10 mg per tablet, and identifies the manufacturer as Carlsbad Technology, Inc. Directions for use are provided in English and Spanish, with placeholders for dosage and timing. The label includes storage instructions, lot, batch, expiration date, and barcode information.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of lovastatin showing its molecular configuration with multiple rings and functional groups represented by standard chemical notation.*

FDA Label Image

Table I (Lov00 0004 02)

A data table showing the effect of coadministered drugs or grapefruit juice on lovastatin exposure, measured by AUC ratios. It includes the number of subjects, dosing details for both the coadministered drug and lovastatin, and quantitative AUC ratio results comparing lovastatin with and without the coadministered substances.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' illustrating the proportion of participants without events over approximately six years of follow-up. Two lines compare Lovastatin and placebo, showing a divergence with Lovastatin associated with a higher proportion of participants without events and a noted 37% risk reduction (p < 0.001). The x-axis represents years of follow-up, and the y-axis shows the proportion of participants without events.*

FDA Label Image

Table Vii (Lov00 0005 04)

A table titled 'Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis' listing interacting agents such as strong CYP3A4 inhibitors, HIV protease inhibitors, gemfibrozil, cyclosporine, danazol, diltiazem, dronedarone, verapamil, amiodarone, and grapefruit juice, along with prescribing recommendations including contraindications or dosage limitations when taken with lovastatin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.